FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2310941128> ?p ?o ?g. }

• W2310941128 endingPage "e0152170" @default.
• W2310941128 startingPage "e0152170" @default.
• W2310941128 abstract "Background Currently, the standard treatment for newly diagnosed glioblastoma multiforme (GBM) is maximal safe surgical resection followed by radiation therapy with concurrent and adjuvant temozolomide. However, disease recurs in almost all patients, and the optimal salvage treatment for recurrent GBM remains unclear. We conducted a systematic review and meta-analysis of published clinical trials to assess the efficacy and toxicities of angiogenesis inhibitors alone as salvage treatment in these patients. Methods Trials published between 1994 and 2015 were identified by an electronic search of public databases (MEDLINE, EMBASE, Cochrane library). Demographic data, treatment regimens, objective response rate (ORR), median progression-free survival (PFS), median overall survival (OS), 6-months PFS rate, 1-year OS and grade 3/4 toxicities were extracted. We also compared the main outcomes of interest between bevacizumab and other angiogenesis inhibitors. All analyses were performed using Comprehensive Meta Analysis software (Version 2.0). Results A total of 842 patients were included for analysis: 343 patients were treated with bevacizumab, 386 with other angiogenesis inhibitors and 81 with thalidomide. The pooled ORR, 6-months PFS, and 1-year OS for recurrent GBM patients receiving angiogenesis inhibitors was 20.1%, 19.5% and 29.3%, respectively. The use of single agent bevacizumab in recurrent GBM significantly improved ORR and 6-months PFS when compared to other angiogenesis inhibitors [relative risk (RR) 2.93, 95% CI 1.38–6.21; p = 0.025; and RR 2.36 95% CI 1.46–3.82; p<0.001, respectively], while no significant difference in 1-year OS was found between the two groups (p = 0.07). when compared to thalidomide, bevacizumab treatment in recurrent GBM significantly improved ORR (RR 6.8, 95%CI: 2.64–17.6, p<0.001), but not for 6-months PFS (p = 0.07) and 1-year OS (p = 0.31). As for grade 3/4 toxicities, the common toxicity was hypertension with pooled incidence of 12.1%, while high-grade thromboembolic events (2.2%), hemorrhage (5.1%) and GI perforation (2.8%) associated with angiogenesis inhibitors were relatively low. Conclusions In comparison with other angiogenesis inhibitors and thalidomide, the use of single agent bevacizumab as salvage treatment for recurrent GBM patients improve ORR and 6-months PFS, but not for 1-year OS." @default.
• W2310941128 created "2016-06-24" @default.
• W2310941128 creator A5000488365 @default.
• W2310941128 creator A5017080859 @default.
• W2310941128 creator A5049692788 @default.
• W2310941128 creator A5072379029 @default.
• W2310941128 creator A5075877965 @default.
• W2310941128 date "2016-03-23" @default.
• W2310941128 modified "2023-10-01" @default.
• W2310941128 title "The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review" @default.
• W2310941128 cites W1567412466 @default.
• W2310941128 cites W179710673 @default.
• W2310941128 cites W1940514332 @default.
• W2310941128 cites W1969328947 @default.
• W2310941128 cites W1979423827 @default.
• W2310941128 cites W1983726466 @default.
• W2310941128 cites W1997397814 @default.
• W2310941128 cites W2052858979 @default.
• W2310941128 cites W2056791786 @default.
• W2310941128 cites W2064792760 @default.
• W2310941128 cites W2065023628 @default.
• W2310941128 cites W2071045537 @default.
• W2310941128 cites W2073477133 @default.
• W2310941128 cites W2073792102 @default.
• W2310941128 cites W2077876620 @default.
• W2310941128 cites W2093783077 @default.
• W2310941128 cites W2096287682 @default.
• W2310941128 cites W2096415778 @default.
• W2310941128 cites W2097459031 @default.
• W2310941128 cites W2097924418 @default.
• W2310941128 cites W2109583483 @default.
• W2310941128 cites W2112268717 @default.
• W2310941128 cites W2114098415 @default.
• W2310941128 cites W2127745545 @default.
• W2310941128 cites W2132697290 @default.
• W2310941128 cites W2133438879 @default.
• W2310941128 cites W2135947790 @default.
• W2310941128 cites W2136240869 @default.
• W2310941128 cites W2136629154 @default.
• W2310941128 cites W2144242568 @default.
• W2310941128 cites W2148977460 @default.
• W2310941128 cites W2156098321 @default.
• W2310941128 cites W2160959204 @default.
• W2310941128 cites W2161190434 @default.
• W2310941128 cites W2164323018 @default.
• W2310941128 cites W2164675211 @default.
• W2310941128 cites W2165772224 @default.
• W2310941128 cites W2165860547 @default.
• W2310941128 cites W2167750533 @default.
• W2310941128 cites W2170367762 @default.
• W2310941128 cites W2314168937 @default.
• W2310941128 cites W246286872 @default.
• W2310941128 cites W2588681363 @default.
• W2310941128 cites W4242403727 @default.
• W2310941128 cites W4294215472 @default.
• W2310941128 doi "https://doi.org/10.1371/journal.pone.0152170" @default.
• W2310941128 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4805294" @default.
• W2310941128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27007828" @default.
• W2310941128 hasPublicationYear "2016" @default.
• W2310941128 type Work @default.
• W2310941128 sameAs 2310941128 @default.
• W2310941128 citedByCount "30" @default.
• W2310941128 countsByYear W23109411282015 @default.
• W2310941128 countsByYear W23109411282016 @default.
• W2310941128 countsByYear W23109411282017 @default.
• W2310941128 countsByYear W23109411282018 @default.
• W2310941128 countsByYear W23109411282019 @default.
• W2310941128 countsByYear W23109411282020 @default.
• W2310941128 countsByYear W23109411282021 @default.
• W2310941128 countsByYear W23109411282022 @default.
• W2310941128 countsByYear W23109411282023 @default.
• W2310941128 crossrefType "journal-article" @default.
• W2310941128 hasAuthorship W2310941128A5000488365 @default.
• W2310941128 hasAuthorship W2310941128A5017080859 @default.
• W2310941128 hasAuthorship W2310941128A5049692788 @default.
• W2310941128 hasAuthorship W2310941128A5072379029 @default.
• W2310941128 hasAuthorship W2310941128A5075877965 @default.
• W2310941128 hasBestOaLocation W23109411281 @default.
• W2310941128 hasConcept C126322002 @default.
• W2310941128 hasConcept C141071460 @default.
• W2310941128 hasConcept C143998085 @default.
• W2310941128 hasConcept C207103383 @default.
• W2310941128 hasConcept C2776056115 @default.
• W2310941128 hasConcept C2776478404 @default.
• W2310941128 hasConcept C2776694085 @default.
• W2310941128 hasConcept C2777389519 @default.
• W2310941128 hasConcept C2777802072 @default.
• W2310941128 hasConcept C2780394083 @default.
• W2310941128 hasConcept C2780739268 @default.
• W2310941128 hasConcept C2780775027 @default.
• W2310941128 hasConcept C44249647 @default.
• W2310941128 hasConcept C509974204 @default.
• W2310941128 hasConcept C535046627 @default.
• W2310941128 hasConcept C71924100 @default.
• W2310941128 hasConcept C95190672 @default.
• W2310941128 hasConceptScore W2310941128C126322002 @default.
• W2310941128 hasConceptScore W2310941128C141071460 @default.
• W2310941128 hasConceptScore W2310941128C143998085 @default.

• next